Clinical Trial Update: MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) [Phase 2]

View source ↗

Summary

Merck completed a Phase 2 trial (MK-7684A-005) evaluating MK-7684A with or without other anticancer therapies in selected solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Neoplasms
• Esophageal Neoplasms
• Gallbladder Neoplasms
• Hepatocellular Carcinoma
• Ovarian Neoplasms
• Squamous Cell Carcinoma of Head and Neck
• Stomach Neoplasms
• Uterine Cervical Neoplasms

Drugs mentioned

• MK-7684A

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Uterine Cervical Neoplasms, Endometrial Neoplasms | Phase 2 | Status: COMPLETED